Brandon Kirsch, MD

Brandon Kirsch, MD, FAAD is a board-certified dermatologist. Dr. Kirsch started his career as a lawyer and holds law degrees from the University of Western Ontario (LL.B.) and Georgetown University (LL.M. Securities and Financial Regulation). He completed medical school at Brown University, an internship at the Mayo Clinic and dermatology residency at the University of North Carolina. He is licensed to practice law in both New York and Ontario, Canada and holds medical licenses in California, Colorado, Florida and North Carolina.

In addition to a busy clinical practice, Dr. Kirsch is the President and Chief Executive Officer at, a dermatologist-led online platform providing personalized prescriptions to treat skin conditions. He has interests in therapeutic drug development and medical innovation. In partnership with the Mayo Clinic, he filed to patent a novel topical composition for the treatment of melasma. He also received a grant from the Mayo Clinic to complete an investigator-initiated pilot study of this formulation.

Dr. Kirsch was previously an Assistant Clinical Professor of Dermatology at the University of Colorado and Medical Director and Vice President of Clinical Development at Brickell Biotech, Inc. At Brickell, Dr. Kirsch provided leadership and strategic direction for the clinical science team. In his role, he had primary responsibility for overseeing development programs from late preclinical to registration Phase 3 randomized studies. Dr. Kirsch has been published in the Journal of the American Medical Association, Journal of the American Academy of Dermatology, Journal of Drugs in Dermatology, Journal of Clinical and Aesthetic Dermatology and the Wall Street Journal.



May/13 Alpert Medical School, Brown University Providence, RI 

Doctor of Medicine 

  • Alpert Medical School Carpenter Traveling Fellowship 
  • Medical Students’ Sustained Training and Research Experience in Aging and Mental Health Scholarship 
  • American Mensa Cooper Memorial Scholarship 
  • Sigma Chi Foundation Walsh Medical Scholarship 

May/09 University of Pennsylvania Philadelphia, PA 

Post-Baccalaureate Pre-Health Program 

May/05 Georgetown University Law Center Washington, DC 

Master of Laws, Securities and Financial Regulation 

  • Dean’s List, With Distinction 

Jun/04 University of Western Ontario London, ON 

Bachelor of Laws 

  • Ontario Law Foundation Graduate Fellowship 

Jun/01 University of Western Ontario London, ON 

Bachelor of Arts, Political Science 

  • Western Scholarship of Distinction 


Mar/06-Present New York State Unified Court System Jul/06-Present Law Society of Upper Canada 


Sep/17-Present Fellow of the American Academy of Dermatology May/17-Present Medical Board of California, License #A149449 May/17-Present Colorado Medical Board, License #DR0058562 Apr/16-Present North Carolina Medical Board, License #218709 July/14-Present Florida Board of Medicine, License #ME120974 


Aug/17- Brickell Biotech Inc. Boulder, CO 

Medical Director 

Jan/18-Sep/18 University of Colorado Boulder, CO 

Assistant Clinical Professor of Dermatology 

Jul/16-Jun/17 University of North Carolina Chapel Hill, NC 

Dermatology Residency (PGY 4) 

Jun/13- Jul/16 Mayo Clinic Jacksonville, FL 

Dermatology Residency, Categorical (PGY 1-3) 

Sep/06-Feb/07 Shearman & Sterling LLP London, UK 

Associate Attorney 

  • Asian and European Capital Markets Practice Group 
  • Drafting and diligence for transactions involving structured finance 

Sep/05-Jul/06 Davies Ward Phillips & Vineberg LLP Toronto, ON 


  • Research, client advocacy and preparation of legal memoranda 

Jan/05-Apr/05 U.S. Securities and Exchange Commission Washington, DC Law Student Observer Program, Division of Enforcement 

  • Prepared civil and administrative cases involving issuers of securities, brokers, dealers and other regulated entities 

Dec/02-May/04 Professor Richard H. McLaren, O.C. London, ON University of Western Ontario, Faculty of Law Research Assistant 

  • Assisted in writing arbitration decisions with respect to doping in professional and amateur sports 
  • Contributed to publications in the areas of secured transactions, debt restructurings and alternative dispute resolution 


Kirsch, B. M., et al. “The Hyperhidrosis Disease Severity Measure-Axillary: Conceptualization and Development of Item Content.” (2018). 

Kirsch, Brandon, and Brian C. Drolet. “The National Resident Matching Program and Competition for Employment.” JAMA 319, no. 17 (2018): 1823-1824. 

Xu S, Allred J, Kirsch B, Raff A, Anderson RR, Ju W. (2016) Training the Next Generation of Innovators in Dermatology. J Invest Dermatol. 2016; 136(11):2113-2115. 

Kirsch, B. M. & Cappel, M. A. (2015). Acute generalized exanthematous pustulosis induced by mifepristone. JAAD Case Reports, 1(4), 191-195. 

Kirsch, B. MD & Sluzevich, J. MD. The generalized rash: part I. Differential diagnosis; The generalized rash: part II. Diagnostic approach. Frank J. Domino, MD, Robert A. Baldor MD, FAAFP, eds. 2015. 5- Minute Clinical Consult – 24th Ed. Philadelphia, PA. Lippincott Williams & Wilkins Health. 

Joseph, R.W., Goedjen B., Gordon, M., Kirsch, B., Gilstrap, C., Bagaria, S. & Jambusaria, A. (2014). Lichenoid dermatitis in three patients with metastatic melanoma treated with anti-PD-1 therapy. Cancer Immunol Res. 2015; 3(1), 18-22. 

Kirsch, B., Grant-Kels, J.M. & Bercovitch, L. (2013). The ethics of “Top Doctor” awards: A tangled web. Journal of the American Academy of Dermatology, 69(5), 792-794. 

Kirsch, B. & Bernstein, M. (2012). Ethical challenges with awake craniotomy for tumor. The Canadian Journal of Neurological Sciences, 39(1), 78-82. 



Kirsch, B, Burke, L, Hobart, J, Angulo, D, Walker, P. Hyperhidrosis Disease Severity Measure-Axillary (HDSM-Ax): Content Development and Measurement Property Testing. (2018). Presented at the South Beach Symposium; Miami, FL. 03/01/2018. 

Smith, S, Kirsch, B, Walker, P. A Multicenter, Randomized, Double-Blinded, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of 5%, 10% and 15% Topically Applied Sofpironium Bromide Gel in Subjects with Axillary Hyperhidrosis. Presented at the Late-breaking Research Forum of the 76th Annual Meeting of the American Academy of Dermatology; San Diego, CA. 02/22/2018. 

Kirsch, B, Hoesly, P, Sluzevich, J. Efficacy and Tolerability of Combination Tazarotene, Azelaic Acid, Tacrolimus and Zinc Oxide for the Treatment of Melasma. (2018). Presented at the 76th Annual Meeting of the American Academy of Dermatology; San Diego, CA. 02/22/2018. 

Training the Next Generation of Innovators in Dermatology. Panelist at the Dermatology Entrepreneurship Conference Residents’ Lunch; San Diego, CA. 02/21/2018. 

Teachers and Trainees Luncheon: Promoting Innovation in Dermatology. Panelist at the Dermatology Entrepreneurship Conference Residents’ Lunch; Orlando, FL. 03/03/2017. 

Careers in Product Innovation. Panelist at the Dermatology Entrepreneurship Conference Residents’ Lunch; Washington, D.C. 03/04/2016. 

Tumoral Melanosis. Dermatopathology Trainee World Cup. Presented at the 19th Joint Meeting of the International Society of Dermatopathology; Washington, D.C. 03/02/2016. 

Oral Therapies for the Treatment of Hyperpigmentation. Presented at the Cosmetic Surgery Forum; Las Vegas, NV. 12/02/15. 

A Fighter’s Guide to Resident Entrepreneurship. Presented at the Advancing Innovation in Dermatology Journal Club as the inaugural resident case study. Virtual. 11/18/2015. 

Acute Generalized Exanthematous Pustulosis Induced by Mifepristone. Presented at the Florida Society of Dermatology and Dermatologic Surgery Annual Meeting; Boca Raton, FL. 04/18/2015. 

Illuminate: Advanced Skin Lightening Composition. Poster presentation at the Dermatology Entrepreneurship Conference; San Francisco, CA. 03/19/2015. 

Treatment of Onychomycosis with Photodynamic Therapy. Presented at Orlando Dermatology Aesthetic and Clinical Conference; Orlando, FL. 01/17/2014. 



Jun 16/2015 Skin Care Composition 

International Application (PCT) for Filing in US Receiving Office 

  • Method for lightening skin color without atrophy or paradoxical hyperpigmentation 


Nov/2015 An Open-Label Pilot Study Evaluating the Effectiveness and Tolerability of a 

Topical Skin Care Composition Therapy (2013-MCN-333) for the Treatment of Melasma Co-Investigator 

  • Under supervision of the Principal Investigator, designed and wrote the Institutional Review Board protocol along with supporting documentation 
  • Successfully petitioned for FDA approval of IND exemption 

RESEARCH GRANTS AWARDED Oct/2015 Accelerate Innovation Grant 

  • Support to accelerate innovation and invention at Mayo Clinic in Florida 
  • Identified the clinical trial of Topical Skin Care Composition (2013- MCN-333) as having commercial promise with the potential for significant patient impact 

INTERESTS and VOLUNTEERISM Mar/16- Advancing Innovation in Dermatology Virtual 

Education Committee Founder, Inaugural Scholars Class of 2016/17 

  • Worked to create a virtual entrepreneurship curriculum and journal club focused on product and service innovations specific to dermatology 
  • Facilitated the development of an externship/internship program enabling trainees in dermatology to explore a variety of career opportunities 

Mar/14-Jun/16 O’Leary Society Board of Directors Jacksonville, FL 

Dermatology Resident Representative 

  • Selected as the resident representative for all three Mayo Clinic sites (Arizona, Florida, Minnesota) 
  • Promoting high-quality dermatologic care, and fostering a strong alumni community; as well as improving residency experience and education 

Nov/13-Mar/14 Mayo Clinic Hospital Practice Committee Jacksonville, FL 

Resident Representative 

  • Ensuring appropriate use of hospital space and facilities in support of patient care 
  • Monitoring compliance with regulatory requirements 

image image image image image image image

© 2020 Minars Dermatology. All rights reserved.